Singer, Peter A., 1960-
Singer, Peter A.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Peter A. Singer Canadian medical researcher
VIAF ID: 24681656 (Personal)
Permalink: http://viaf.org/viaf/24681656
Preferred Forms
-
100 0 _
‡a
Peter A. Singer
‡c
Canadian medical researcher
-
200 _ |
‡a
Singer
‡b
Peter A.
‡f
1960-....
-
100 1 _ ‡a Singer, Peter A.
-
100 1 _
‡a
Singer, Peter A.
-
100 1 _ ‡a Singer, Peter A.
-
100 1 _
‡a
Singer, Peter A.
‡d
1960-
-
100 1 _
‡a
Singer, Peter A.
‡d
1960-...
-
100 1 _ ‡a Singer, Peter A., ‡d 1960-
-
100 1 _
‡a
Singer, Peter A.,
‡d
1960-
-
100 1 _ ‡a Singer, Peter A., ‡d 1960-
-
100 1 _
‡a
Singer, Peter A.,
‡d
1960-
-
100 1 _ ‡a Singer, Peter A., ‡d 1960-
-
100 1 _ ‡a Singer, Peter A., ‡d 1960-
-
100 1 _ ‡a Singer, Peter A., ‡d 1960-
4xx's: Alternate Name Forms (9)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| Bioethics at the bedside : a clinician's guide |
|
| The Cambridge textbook of bioethics, 2008: |
|
| The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries |
|
| The ELSI genetics regulatory resource kit: a tool for policymakers in developing countries |
|
| The emergence of Egyptian biotechnology from generics |
|
| Fairness, accountability for reasonableness, and the views of priority setting decision-makers. |
|
| Franchising rabies vaccine delivery: the case of Indian immunologicals |
|
| From the editors: Bob Dent's decision |
|
| The future of Baby Doe. |
|
| Genetically engineered oil-eating microbes for bioremediation: Prospects and regulatory challenges |
|
| Genomics--a global public good? |
|
| Global health. Stagnant health technologies in Africa |
|
| Grand challenges in chronic non-communicable diseases |
|
| Grand challenges in global health: the ethical, social and cultural program |
|
| Grand challenges in humanitarian aid |
|
| The grandest challenge : taking life-saving science from lab to village |
|
| Harnessing biodiversity: the Malagasy Institute of Applied Research (IMRA) |
|
| Harnessing stem cells for health needs in India |
|
| Health biotechnology in China--reawakening of a giant |
|
| Health Innovation Networks to Help Developing Countries Address Neglected Diseases |
|
| Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada |
|
| Hospital policy on appropriate use of life-sustaining treatment |
|
| Human-animal chimeras for vaccine development: an endangered species or opportunity for the developing world? |
|
| In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs? |
|
| The incommensurability of research risks and benefits: practical help for research ethics committees. |
|
| The Indian and Chinese health biotechnology industries: potential champions of global health? |
|
| Indian biotechnology--rapidly evolving and industry led |
|
| Indian vaccine innovation: the case of Shantha Biotechnics |
|
| India's health biotech sector at a crossroads |
|
| Innovative drugs and vaccines in China, India and Brazil |
|
| Introduction: promoting global health through biotechnology |
|
| Is there an ethical obligation to complete polio eradication? |
|
| Isolationism is not the answer to bioterrorism |
|
| Leadership and priority setting: the perspective of hospital CEOs. |
|
| Legal and ethical approaches to stem cell and cloning research: a comparative analysis of policies in Latin America, Asia, and Africa |
|
| Lessons on ethical decision making from the bioscience industry |
|
| Living will. |
|
| Management of thyroid and parathyroid disorders |
|
| Medical ethics, c1988: |
|
| Mind the gap : science and ethics in nanotechnology |
|
| More on euthanasia: a response to Pauer-Studer. |
|
| Non-Western bioethics. |
|
| North-South partnerships--a study of Canadian firms |
|
| Of genes, embryos, human individuals and future persons |
|
| On the ethics of bringing people into existence |
|
| Pharmacogenetics and geographical ancestry: implications for drug development and global health |
|
| Priority setting in a hospital drug formulary: a qualitative case study and evaluation |
|
| Public engagement on global health challenges |
|
| Questionable experiments, muddled defence. |
|
| Randomization in controlled trials. |
|
| Regenerative medicine and the developing world |
|
| Regenerative Medicine in Brazil: Small but Innovative |
|
| Reprint: When Shall We Be Free? |
|
| The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan |
|
| Science-based health innovation in Ghana: health entrepreneurs point the way to a new development path |
|
| Science community: scientific diasporas |
|
| Science, Society, and the Supermarket |
|
| The scientific muscle of Brazil's health biotechnology |
|
| Sex, gender, and health biotechnology: points to consider |
|
| Shared principles of ethics for infant and young child nutrition in the developing world |
|
| Small but tenacious: South Africa's health biotech sector |
|
| South Africa--blazing a trail for African biotechnology |
|
| South Africa: from species cradle to genomic applications |
|
| South Korean biotechnology--a rising industrial and scientific powerhouse |
|
| Still no academic freedom in Germany |
|
| Strengthening the role of genomics in global health |
|
| Top ten biotechnologies for improving health in developing countries |
|
| Turning science into health solutions: KEMRI's challenges as Kenya's health product pathfinder |
|
| Universal health care, genomic medicine and Thailand: investing in today and tomorrow |
|
| University of Toronto Joint Centre for Bioethics living well |
|
| Venture capital on a shoestring: Bioventures' pioneering life sciences fund in South Africa |
|
| Venture funding for science-based African health innovation |
|
| Whose life? |
|
